AMRX
Amneal Pharmaceuticals, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +1.8% · net new positions 0.0% — formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 101 | -4 | 106.56M | $1.84B | +7 | −10 |
| Q1 2026 | 107 | -1 | 100.53M | $1.25B | +9 | −11 |
| Q4 2025 | 109 | 0 | 106.30M | $1.34B | +1 | — |
| Q3 2025 | 18 | 0 | 61.16M | $612.26M | — | — |
| Q2 2025 | 15 | -1 | 52.63M | $425.79M | — | −1 |
| Q1 2025 | 13 | +3 | 21.14M | $177.14M | +3 | — |
| Q4 2024 | 10 | -1 | 20.64M | $163.48M | — | −1 |
| Q3 2024 | 10 | 0 | 16.87M | $140.36M | +2 | −2 |
| Q2 2024 | 10 | — | 16.56M | $105.19M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Citadel Advisors ✦ | 8.89M | -11.0% | $73.98M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 3.79M | +11.1% | $31.51M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 3.79M | +11.1% | $31.51M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | Arrowstreet Capital ✦ | 2.07M | +158.8% | $17.21M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | Millennium Management ✦ | 817.58K | -12.1% | $6.80M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 6 | Renaissance Technologies ✦ | 755.60K | +10.7% | $6.29M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | AQR Capital Management ✦ | 303.25K | -30.3% | $2.52M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 8 | AQR Capital Management ✦ | 303.25K | -30.3% | $2.52M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 303.25K | -30.3% | $2.52M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 10 | T. Rowe Price ✦ | 87.55K | +1.8% | $729,000 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | Wellington Management ✦ | 82.60K | New | $687,198 | 0.0% | New | 1 | SEC ↗ |
| 12 | Wellington Management ✦ | 82.60K | New | $687,198 | 0.0% | New | 1 | SEC ↗ |
| 13 | Wellington Management ✦ | 82.60K | New | $687,198 | 0.0% | New | 1 | SEC ↗ |
| 14 | Wellington Management ✦ | 82.60K | New | $687,198 | 0.0% | New | 1 | SEC ↗ |
| 15 | Gotham Asset Management ✦ | 47.66K | New | $396,523 | 0.0% | New | 1 | SEC ↗ |
| 16 | Two Sigma Investments ✦ | 27.25K | -52.9% | $226,678 | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Wellington Management | $687,198 | 0.0% |
| Wellington Management | $687,198 | 0.0% |
| Wellington Management | $687,198 | 0.0% |
| Wellington Management | $687,198 | 0.0% |
| Gotham Asset Management | $396,523 | 0.0% |
Exited
| D. E. Shaw & Co. | $570,833 | was 0.0% |
| Norges Bank | $547,370 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 314 holders, 158.91M shares, $1.92B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 50.00K sh · $882,000
Officer · 146.40K sh · $2.56M
Officer · 210.00K sh · $3.65M
Officer · 6.61K sh · $117,050
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
17.6% of class · View original SEC filing ↗
8.4% of class · View original SEC filing ↗
9.4% of class · View original SEC filing ↗